Here, the authors show that PPDPF inhibits the development of hepatic steatosis by negatively regulating mTORC1-S6K-SREBP1 signaling, which provides a potential therapeutic candidate for NAFLD treatment. Here, RPS6KB1 is linked to metabolic dysfunction-associated steatotic liver disease.